HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

Fletikumab

targets interleukin-20 for treatment of rheumatoid arthritis

Also Known As:

NNC-0109-0012; NNC01 09-0012; NNC0109-0012

Networked: 4 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Göthberg, Marie: 3 articles (06/2015 - 01/2015)
2.	Andersen, Thomas: 1 article (01/2018)
3.	Deleuran, Bent: 1 article (01/2018)
4.	Gerwien, Jens: 1 article (01/2018)
5.	Heftdal, Line D: 1 article (01/2018)
6.	Hvid, Malene: 1 article (01/2018)
7.	Kragstrup, Tue W: 1 article (01/2018)
8.	Senolt, Ladislav: 1 article (01/2018)
9.	Sivakumar, Pallavur: 1 article (01/2018)
10.	Taylor, Peter C: 1 article (01/2018)

Related Diseases

1.	Psoriasis (Pustulosis Palmaris et Plantaris) 01/01/2015 - "Single and multiple doses of NNC0109-0012, ranging from 0.05 to 3.0 mg/kg, were well tolerated in patients with psoriasis and exhibited pharmacokinetics similar to that of other monoclonal antibodies. " 03/01/2015 - "Clinical pharmacokinetics of the anti-interleukin-20 monoclonal antibody NNC0109-0012 in healthy volunteers and patients with psoriasis or rheumatoid arthritis." 01/01/2018 - "Clinical trials that investigate inhibitors of IL-20 (fletikumab) and IL-22 (fezakinumab) in psoriasis and RA have been terminated. "
2.	Nasopharyngitis 06/01/2015 - "The most frequent adverse events reported with NNC0109-0012 were injection site reactions and infections (e.g., herpes, nasopharyngitis, respiratory, and urinary). "
3.	Infections 06/01/2015 - "No serious infections or discontinuations associated with NNC0109-0012 were observed. " 06/01/2015 - "The most frequent adverse events reported with NNC0109-0012 were injection site reactions and infections (e.g., herpes, nasopharyngitis, respiratory, and urinary). "
4.	Rheumatoid Arthritis 03/01/2015 - "Clinical pharmacokinetics of the anti-interleukin-20 monoclonal antibody NNC0109-0012 in healthy volunteers and patients with psoriasis or rheumatoid arthritis."
5.	Injection Site Reaction 06/01/2015 - "The most frequent adverse events reported with NNC0109-0012 were injection site reactions and infections (e.g., herpes, nasopharyngitis, respiratory, and urinary). "

Related Drugs and Biologics

1.	Interleukin-22 (IL-22)
2.	interleukin 20 (IL-20)
3.	fezakinumab
4.	Monoclonal Antibodies